Masimo to Release Third Quarter 2021 Financial Results After Market Close on Tuesday, October 26

0

IRVINE, Calif .– (COMMERCIAL THREAD) – Masimo (NASDAQ: MASI) will release third quarter 2021 financial results for the period ending October 2, 2021, following market close on Tuesday, October 26, 2021. The conference call to review the results will begin at 1:30 pm. pm PT (4:30 p.m. ET) and will be moderated by Joe Kiani, President and CEO, and Micah Young, Executive Vice President and CFO.

To register for the conference call and receive the call number, please use the link below. Upon registration, each participant will receive call details and a registrant identification number. Reminders regarding the call will also be sent to registered participants by email.

Conference call registration link:

http://www.directeventreg.com/registration/event/5492005

A replay of the webcast and conference call will be available shortly after the call ends and will be archived on the Company’s website.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide range of cutting-edge monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes, reduce the cost of care, and expand non-invasive monitoring to new sites and applications. Masimo SET® Measure-through Motion and Low Perfusion ™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in newborns, improve screening for CCHD in newborns, and, when used for continuous monitoring with Masimo Patient SafetyNet ™ in postoperative wards, reduces rapid response team activations, intensive care transfers and costs. Masimo SET® is estimated to be used on more than 200 million patients in major hospitals and other healthcare facilities around the world, and is the main pulse oximetry in 9 of the top 10 hospitals according to the 2021-2022 ranking American News and World Report Best hospital honor roll. Masimo continues to refine SET® and in 2018, announced that SpO2 precision on RD SET® sensors during motion conditions has been significantly improved, providing clinicians with even greater confidence than SpO2 the values ​​on which they are based accurately reflect the physiological state of a patient. In 2005, Masimo introduced Rainbow® Pulse CO-oximetry technology, enabling non-invasive and continuous monitoring of blood components that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC ™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth variability index (PVi®), RPVi ™ (rainbow® PVi) and the oxygen reserve index (ORi ™). In 2013, Masimo introduced the Root® Patient monitoring and connectivity platform, designed from the ground up to be as flexible and extensible as possible to facilitate the addition of other Masimo and third-party monitoring technologies; Masimo’s key additions include the next generation of SedLine® Brain function monitoring, O3® ISA ™ regional oximetry and capnography with NomoLine® sampling lines. The Masimo family of pulse CO-oximeters with continuous and spot monitoring® includes devices designed for use in a variety of clinical and non-clinical scenarios, including portable wireless technology, such as Radius-7® and Radius PPG ™, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx and devices available for both hospital and home use, such as Rad-97®. Masimo’s hospital automation and connectivity solutions are centered on the Masimo Hospital Automation ™ platform and include Iris® Gateway, iSirona ™, Patient SafetyNet, Replica ™, Halo ION ™, UniView®, UniView: 60 ™ and Masimo SafetyNet ™. Additional information about Masimo and its products is available at www.masimo.com. Published clinical studies for Masimo products are available at www.masimo.com/evidence/featured-studies/feature/.

ORi and RPVi have not received 510 (k) clearance from the FDA and are not available for sale in the United States. Use of the Patient SafetyNet trademark is under license from the University HealthSystem Consortium.

Masimo, SET, signal extraction technology, improved patient outcomes and reduced costs of care by introducing non-invasive monitoring to new sites and applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo.

Share.

Leave A Reply